Today's Brief

Updated daily.

Get the free BIOTECH brief in 5 minutes.

A free daily and weekly email that tells you what changed, what is noise, and where to verify it at the source.

Start with the short list before you open another feed.
See what is continuing versus what is only today's spike.
Open the original sources in one click when you want to verify.

Free daily + weekly email

Free by email: Today’s Brief (daily) + This Week’s Brief (weekly). Upgrade later for archive, alerts, search, exports, API, and workflow.

Get tomorrow's brief by email

One field, compact consent, daily + weekly by default.

How it works Open featured signal

What you would receive

Featured now

GSK’s hepatitis B drug achieves functional cure in nearly one-fifth of patients in phase 3 trials

GSK and Ionis Pharmaceuticals reported phase 3 trial results for bepirovirsen, showing nearly 20% of patients with chronic hepatitis B achieved a functional cure.

Why now: Phase 3 trial results have just been released, confirming efficacy in a large patient population.

biopharmadive.com
BioPharma Dive
pharmaphorum
GSK hails 'unprecedented' cure rates with hep B drug
Fierce Biotech
GSK is pulling back the curtain on the phase 3 success of its chronic hepatitis B drug bepirovirsen, revealing that nearly one-fifth of all treated patients ...

All source links included.

Open today's sample Browse signals

Read today's brief Browse signals

Today’s strongest item first

The homepage leads with an editorially featured signal alongside the open brief, while current signals stay open across the site.

Proof, not boilerplate

3 real source links are already visible in today’s public example.

Free brief before upgrade

Get the daily + weekly brief by email first. Upgrade only if you need archive, alerts, search, exports, API, and deeper workflow tools.

What lands in your free brief

Start with the brief, then drill down only on the items that matter.

Briefing item

FDA delays decision on Beren Therapeutics’ rare disease drug; Sanofi’s Gaucher drug decision set for November

The FDA has extended its review of Beren Therapeutics’ rare disease drug candidate, further delaying its potential U.S. market entry. In contrast, the FDA has scheduled a decision for November on Sanofi’s drug for Gaucher disease, providing a clearer near-term regulatory milestone for that asset.

Why now: Beren Therapeutics’ extended review reflects current FDA scrutiny on rare disease drugs.

CurrentSource diversity aware

Sources: 2

See details ->

Briefing item

Advances in bioinformatics and machine learning enhance biomarker discovery and protein expression prediction

Recent studies demonstrate innovative applications of bioinformatics and machine learning to improve precision medicine and proteome-wide association studies.

Why now: Availability of large-scale multi-omics and proteomic datasets enables advanced computational analyses.

CurrentSource diversity aware

Sources: 2

See details ->

Briefing item

Advances in optical imaging and mid-infrared biosensing technologies

Recent developments include the STIMscope, a benchtop one-photon microscope enabling large-scale all-optical imaging and patterned optogenetic manipulation at single-cell resolution, and SPAC-OTHES, a compact mid-infrared optothermal spectrometer with enhanced spectral...

Why now: STIMscope and SPAC-OTHES represent recent innovations published in 2026, reflecting current advances in optical biomedical tools.

CurrentSource diversity aware

Sources: 2

See details ->

How it works

Built to save you time while keeping every key point easy to verify.

Read widely

News, social, dev channels, and primary sources.

Remove duplicates

Filter rewrites, SEO clones, and repeated takes.

Group what belongs together

So you see one story, not 20 scattered posts.

Deliver the briefing

A daily scan + drill-down with source links.

See Methodology

Start free, upgrade only if you need more

Start with the free brief if you want the signal first, not an hour of scrolling. It gives you the short list, the context, and the source links in one pass.

Upgrade later only if you need memory, alerts, archive, exports, API, and recurring workflow for ongoing research work.

Why people start with the free brief

Daily brief

The 5-minute version of what genuinely changed since yesterday.

Momentum over time

See what is building, peaking, or fading across days and weeks.

Source links included

Jump to the originals when you need to verify a claim fast.

Free daily + weekly emailUpgrade only when you need full drill-down

Get the free brief

See pricing This Week’s Brief

Product tour

A short walkthrough of the BIOTECH dashboards.